T-Cells For The Win With Adaptimmune's Adrian Rawcliffe

Business Of Biotech

We love to hear from our listeners. Send us a message.

In August of this year, the first TCR cell therapy to be approved for use in the U.S. was greenlighted by the FDA for patients with resectable or metastatic synovial sarcoma who have previously received chemotherapy. It marked the first new treatment for those patients in more than a decade; a win for those patients, and a win for Adrian Rawcliffe, who’s had a hand on the wheel at Adaptimmune, the therapy’s developer and manufacturer, since he joined the company as CFO in 2015. Today, Rawcliffe is CEO there, and on this episode of the Business of Biotech, we’re going to get to know him, why he’s all-in on cell therapies, and how he’s applying a solid track record in finance and business development to make good on the promise they offer.

Access this and hundreds of episodes of the Business of Biotech videocast under the Listen & Watch tab at bioprocessonline.com.

Subscribe to our monthly Business of Biotech newsletter.
Get in touch with guest and topic suggestions: [e-mail]
Find Matt Pillar on LinkedIn: https://www.linkedin.com/in/matthewpillar/

บท

1. T-Cells For The Win With Adaptimmune's Adrian Rawcliffe (00:00:00)

2. Adrian Rockliff's Journey in Cell Therapy (00:00:04)

3. Value Creation in Cell Therapy Capabilities (00:15:41)

4. Strategic Implications of Cell Therapy Manufacturing (00:24:26)

5. Evolution of Cell Therapy Manufacturing (00:40:11)

6. Lessons From CEO on Biotech Leadership (00:47:33)